Survivin-based vaccine, composed of a pool of three SLPs with eight CD4+ epitopes and six CD8+ epitopes, has shown to activate both CD4+ and CD8+ immune responses in mouse models for colorectal cancer. Here, CD4 is linked to colorectal cancer.